InnoCare Pharma Moves to Modernize Governance With New Corporate Charter

The latest announcement is out from InnoCare Pharma Ltd. ( (HK:9969) ).

InnoCare Pharma has proposed amendments to its existing memorandum and articles of association to align its corporate constitution with recent changes to Hong Kong listing regulations. The revisions would permit the cancellation or holding of repurchased shares as treasury shares, expand support for hybrid and electronic general meetings with e-voting, and facilitate the electronic payment of dividends, alongside other consequential and housekeeping updates.

The board plans to replace the current constitutional documents with a sixth amended and restated memorandum and articles of association, which will only take effect if shareholders approve a special resolution at the upcoming annual general meeting. The move is expected to modernize InnoCare’s governance framework, enhance operational flexibility in capital management and shareholder communications, and bring its practices in line with the exchange’s evolving paperless and digital regime.

The most recent analyst rating on (HK:9969) stock is a Hold with a HK$11.50 price target. To see the full list of analyst forecasts on InnoCare Pharma Ltd. stock, see the HK:9969 Stock Forecast page.

More about InnoCare Pharma Ltd.

InnoCare Pharma Limited is a Hong Kong-listed biopharmaceutical company focused on the discovery, development and commercialization of innovative therapies. The company operates in the pharmaceutical and life sciences industry, targeting unmet medical needs and leveraging capital markets access via its listing on the Hong Kong Stock Exchange to support growth and R&D investment.

Average Trading Volume: 6,876,447

Technical Sentiment Signal: Sell

Current Market Cap: HK$17.58B

For detailed information about 9969 stock, go to TipRanks’ Stock Analysis page.